Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of
Sintilimab injection combined with Inlyta in fumarate hydratase-deficient renal cell
carcinoma.